Cargando…

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors

Immunotherapy has revolutionized the treatment of both hematological malignancies and solid tumors. The use of immunotherapy has improved outcome for patients with cancer across multiple tumor types, including lung, melanoma, ovarian, genitourinary, and more recently breast cancer with durable respo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vikas, Praveen, Borcherding, Nicholas, Chennamadhavuni, Adithya, Garje, Rohan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228136/ https://www.ncbi.nlm.nih.gov/pubmed/32457830 http://dx.doi.org/10.3389/fonc.2020.00570

Ejemplares similares

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
por: Swami, Umang, et al.
Publicado: (2020)

Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma
por: An, Josiah, et al.
Publicado: (2022)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
por: Sunkara, Tejasvi, et al.
Publicado: (2022)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

Association between diabetes mellitus and poor patient outcomes after out-of-hospital cardiac arrest: A systematic review and meta-analysis
por: Voruganti, Dinesh Chandra, et al.
Publicado: (2018)

Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review)
por: Jin, Ning, et al.
Publicado: (2023)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
por: Li, Shan, et al.
Publicado: (2021)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity
por: Horton, Julie K., et al.
Publicado: (2013)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
por: Hunia, Jaromir, et al.
Publicado: (2022)

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
por: Pu, Dan, et al.
Publicado: (2021)

The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
por: Reinbolt, Raquel E., et al.
Publicado: (2013)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

Editorial: Novel immunotherapies to treat gastrointestinal solid tumor cancers
por: Sureban, Sripathi M., et al.
Publicado: (2022)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
por: De Lorenzo, Silvana B., et al.
Publicado: (2013)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination
por: Fernandes, Marta Pina, et al.
Publicado: (2023)

The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
por: Garje, Rohan, et al.
Publicado: (2020)

Editorial: Advances in Combination Tumor Immunotherapy
por: Curran, Michael A., et al.
Publicado: (2015)

Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
por: Nayyar, Gaurav, et al.
Publicado: (2019)

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
por: Peyraud, Florent, et al.
Publicado: (2020)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
por: Bian, Yuan, et al.
Publicado: (2022)

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
por: Shah, Girish M., et al.
Publicado: (2013)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

ALDH1: A potential therapeutic target for cancer stem cells in solid tumors
por: Wei, Yaolu, et al.
Publicado: (2022)

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
por: Caputo, Roberta, et al.
Publicado: (2023)

CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
por: Filley, Anna C., et al.
Publicado: (2018)

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
por: Alhusaini, Abdullah, et al.
Publicado: (2021)

The potential of PARP as a therapeutic target across pediatric solid malignancies
por: Keller, Kaylee M., et al.
Publicado: (2023)

Ferroptosis and tumor immunotherapy: A promising combination therapy for tumors
por: Cai, Huazhong, et al.
Publicado: (2023)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q7v9fm9439e631hbcoej2g2ovl